PALOMA PEREZ: Open Payments
NPI 1174275614 · ONALASKA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,246 in 58 payments from 11 companies in 2025. Trend: 2023 $2,086 · 2024 $1,938 · 2025 $2,246
Food & beverage: $2,246
| Company | Payments | Amount |
|---|---|---|
| Lumenis BE inc | 1 | $849 |
| AstraZeneca Pharmaceuticals LP | 14 | $696 |
| GlaxoSmithKline, LLC. | 12 | $164 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $149 |
| ABBVIE INC. | 8 | $140 |
| Galderma Laboratories, L.P. | 4 | $92 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $51 |
| PFIZER INC. | 2 | $34 |
| Lilly USA, LLC | 2 | $34 |
| Novo Nordisk Inc | 1 | $20 |
Products named: M22, FARXIGA, TRELEGY ELLIPTA, XIFAXAN, UBRELVY, AIRSUPRA, Kerendia, DYSPORT.
Industry payments across TX — which companies pay providers there.
